Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
about
Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphomaChemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin LymphomaThe evolving role of response-adapted PET imaging in Hodgkin lymphomaThe role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseHodgkin lymphoma, version 2.2015.Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review.Avoidable mortality across Canada from 1975 to 1999Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Role of chemotherapy in Hodgkin's lymphoma.Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?Role of Radiotherapy in Modern Treatment of Hodgkin's LymphomaThe Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Hodgkin's lymphoma therapy: past, present, and future.Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignanciesInterim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and CaveatsStage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience.Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.Current knowledge and future research directions in treatment-related second primary malignancies.Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.Comparative study of two mechlorethamine, vincristine, procarbazine, and prednisone derived chemotherapeutic protocols for the management of pediatric Hodgkin lymphoma (HL): single-center 5-year experience.An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETThe Management of Classical Hodgkin's Lymphoma: Past, Present, and FutureCurrent concepts and controversies in the management of early stage Hodgkin lymphoma.Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.FDG-PET/CT based response-adapted treatment.Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.Hodgkin's lymphoma: molecular targets and novel treatment strategies.Novel therapies for Hodgkin Lymphoma.PET and PET/CT for response evaluation in lymphoma: current practice and developments.FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-upMinimizing late effects in children and adults with Hodgkin lymphoma - the beginning of the end for radiation therapy.Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage.Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.
P2860
Q24236589-BA1F3E34-FDD8-4388-BAD1-4D87E3386C4BQ24243379-9A19E135-072B-437E-BC75-137388BE3F77Q26750993-2C4BB347-DC29-47AF-8804-677EF9CE947DQ26858893-E648A4AA-30F0-4D0E-AC7C-74B3A4150D02Q30769157-E7B056DA-40FE-42A5-B163-7E7E1BDB3CCAQ30937299-35EE18B7-4EDF-4AD4-84B5-BAD6CA2078A0Q33244267-22759A07-7C0E-43D0-A917-517176C40390Q33704061-EB8F8EB2-A6BC-4017-A504-C765B2AB19D7Q33761103-048890F4-21EE-4BFF-ABB3-93F1BC313B44Q34095620-156E7065-3368-468A-8FBB-F3C3826413D3Q34185759-E5C43EA8-DD9C-4AF7-9565-7053FBA8806FQ34235785-F37A57DE-9C93-4A70-96D5-957798698293Q34240314-9DC08276-D0FE-475E-A350-513F90A4F578Q34296914-7F5EE4D4-3DA2-44AF-9F5D-3F4D45059C84Q34473445-EAA58993-1913-4B6B-8688-91AF8C1E3213Q34475763-C55164A8-E844-40E6-BDC4-9749B69210AEQ34486551-3E8E2869-D564-477A-9F70-0737F1C8D7BBQ34495333-DD15662D-6776-4EC0-9BB1-F7882A48697CQ34604460-C410804B-02D1-4F86-A258-CAC8EB0A7757Q34610653-851977B1-0CEE-4E7A-ACAB-8EDDBA762BA4Q34617599-C9495EA1-541C-45BA-85CB-E8564C026E57Q35016354-EA24F0D9-3724-40C6-A960-657C07B5C408Q35029924-DD5BFC3C-33C1-42A5-BCA0-9C99FDD8377FQ35038852-E4164921-0DBB-4FE5-9BC2-E22990C0CD27Q36061643-71338713-BACD-4167-909A-E59C6230E47FQ36135751-C7938C90-AC60-4586-9212-8667F15BA698Q36286595-3541340C-FDFD-4DC9-8ECF-B92707C0D36EQ36440046-FB330461-F073-40CB-8E6A-710D04BE5D88Q36572545-F5FAA7F4-DE05-487A-BCD6-1CB4304102FAQ36612532-9D295F44-6E1B-4846-A96C-316470644647Q36746441-909959C6-A151-4D89-A3A5-07035C574F37Q36838768-8979B2BD-561E-441C-9BC8-E4D5AC5DB14BQ37146056-B52B0CB3-63A8-4291-B536-3C84C86B96D9Q37157419-E82F449E-D0A5-4F3D-899D-00729953746BQ37304122-26A6B364-C0CB-415F-ABF9-752547C87314Q37330672-B6000266-2B75-41A4-8466-6A64FC96EC7EQ37383554-69A8D662-B200-479A-94CF-C2F1266F6738Q37563122-D8ACCC74-7C00-441F-8D56-F77F5D170310Q37598106-3E1BFEB3-9667-4C93-A428-5E4F1B82437BQ37672032-C65CF7F7-7D5E-4377-A375-FE2535651B8D
P2860
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Randomized comparison of ABVD ...... rn Cooperative Oncology Group.
@en
Randomized comparison of ABVD ...... rn Cooperative Oncology Group.
@nl
type
label
Randomized comparison of ABVD ...... rn Cooperative Oncology Group.
@en
Randomized comparison of ABVD ...... rn Cooperative Oncology Group.
@nl
prefLabel
Randomized comparison of ABVD ...... rn Cooperative Oncology Group.
@en
Randomized comparison of ABVD ...... rn Cooperative Oncology Group.
@nl
P2093
P50
P921
P356
P1476
Randomized comparison of ABVD ...... rn Cooperative Oncology Group.
@en
P2093
A Rashid Dar
Andrea Bezjak
Bruce F Burns
Jane N Winter
Keyue Ding
Lois E Shepherd
Marina S Djurfeldt
Mary K Gospodarowicz
Ralph M Meyer
Robert G Pearcey
P304
P356
10.1200/JCO.2005.09.085
P407
P50
P577
2005-04-18T00:00:00Z